Home Latest Articles
Latest Articles
  • Wenchao LIU, Shujuan LIANG, Xianlei WANG
    World Clinical Drug. 2022, 43(9): 1124-1129.
    Objective

    To study the efficacy and safety of propofol combined with esketamine for sedation during endoscopic retrograde cholangiopancreatography (ERCP).

    Methods

    A total of 100 patients who received ERCP in first hospital of Qinhuangdao from January 2020 to January 2021 were selected for prospective study. The patients were divided into group A (intravenous anesthesia with propofol combined with esketamine) and group B (intravenous anesthesia with propofol combined with fentanyl) according to the random number table method, 50 cases in each group. The scores of sedation were compared between the two groups. Heart rate, mean arterial pressure (MAP) and blood oxygen saturation (SpO2) were recorded before anesthesia (T0), after induction (T1), through oral endoscopy (T2), after surgery (T3) and after recovery (T4) in both groups. The operation time, recovery time, total dosage of propofol and the incidence of adverse reactions were compared between the two groups.

    Results

    The sedation score of group A was significantly better than that of group B (P<0.05). The main effects of time and method on heart rate, MAP and SpO2 levels were significant (P<0.05). There was no interaction effect between time and method on heart rate, MAP and SpO2 levels (P>0.05). The heart rate of group A was higher than that of group B at T4 (P<0.05). MAP and SpO2 in group A were higher than those in group B at T3 and T4 (P<0.05). The time of recovery in group A was shorter than that in group B, and the dosage of propofol in group A was less than that in group B (P<0.05). The total incidence of adverse reactions in group A was lower than that in group B (P<0.05).

    Conclusion

    Esketamine combined with propofol in ERCP anesthesia can provide effective sedative and analgesic effect, has advantages in maintaining intraoperative hemodynamic stability, and can reduce the dosage of anesthetic drugs, shorten the time to wake up, and reduce the incidence of adverse reactions, which is a safe and effective anesthesia program.

  • Weiwei WANG, Daqing WANG, Shuangqing CAO
    World Clinical Drug. 2022, 43(9): 1130-1137.
    Objective

    To investigate the effectiveness and safety of anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

    Methods

    A total of 40 patients with ES-SCLC who had relapsed after the first-line treatment admitted to Harrison international peace hospital from February 2020 to June 2022 were selected and randomly divided into the observation group and control group, 20 cases in each group. The patients in the control group received hyperthermia chemotherapy with irinotecan and the patients in the observation group were treated with anlotinib based on the control group (took it for 2 weeks and stopped for 1 week). Every 3 weeks was a cycle. The efficacy and adverse reactions of the two groups were compared.

    Results

    After 2 cycles of chemotherapy, total effective rate for solid tumors, disease control rate of tumors, progression-free survival (PFS) and overall survival (OS) of the observation group were higher than those of the control group (P<0.05). The serum levels of carcinoembryonic antigen, carbohydrate antigen 125, cytokeratin 19 fragment antigen 21-1, pro-gastrin-releasing peptide, neuron-specific enolase of the observation group were higher than those of the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups during chemotherapy (P>0.05). The serum levels of vascular endothelial growth factor and angiopoietin-2 of the observation group were higher than those of the control group (P<0.05).

    Conclusion

    Anlotinib combined with hyperthermia chemotherapy in the second-line treatment of patients with ES-SCLC can improve the short-term efficacy, reduce the level of serum tumor markers, inhibit tumor angiogenesis, prolong PFS and OS, and it is safe and reliable.

  • Jingrui DUAN, Yuwei CAI, Yan XUE, Jian ZHANG, Xinfeng GU, Yuelong CAO, Yuxin ZHENG
    World Clinical Drug. 2022, 43(9): 1138-1142.
    Objective

    To observe the clinical effects of diphosphate combined with active vitamin D in the treatment of knee osteoarthritis (KOA) with osteoporosis (OP).

    Methods

    A total of 98 patients with KOA and OP in the department of osteoarthritis, Shuguang hospital affiliated to Shanghai university of traditional Chinese medicine from March 2015 to February 2017 were selected, and randomly divided into observation group and control group, with 49 cases in each group. The observation group was treated with diphosphate combined with active vitamin D orally, and the control group was treated with glucosamine sulfate capsules combined with active vitamin D orally. The course of treatment was 3 months. The bone mineral density (BMD), visual analog scale (VAS) scores, Western Ontario and McMaster University of Orthopedic Index (WOMAC) of the femoral neck were measured to evaluate the degree of OP and knee pain before and after treatment.

    Results

    After 3 months of treatment, BMD increased in both groups, and the difference between the two groups was statistically significant (P<0.05). After 2 months of treatment, the VAS and WOMAC scores decreased between the two groups, and the difference in WOMAC scores between the two groups were statistically significant (P<0.05). After 3 months of treatment, the knee VAS scores and WOMAC of the two groups were lower than those before treatment, and the differences between the groups were statistically significant (P<0.05).

    Conclusion

    Diphosphate combined with active vitamin D has a good effect on improving KOA combined with OP, which is worthy of further clinical promotion.

  • Wei ZHOU, Yun TAO, Lin HAN, Zhiyun XU, Bailing LI, Hao CHENG
    World Clinical Drug. 2022, 43(9): 1143-1147.
    Objective

    To investigate the effects of nafamostat mesilate as an anticoagulant in patients at high risk of bleeding after cardiovascular surgery undergoing continuous renal replacement therapy (CRRT).

    Methods

    Twenty-seven patients with high risk of bleeding who underwent CRRT after cardiovascular surgery in the first affiliated hospital of naval medical university from August 2021 to April 2022 were enrolled. According to the different anticoagulants, the patients were divided into anticoagulant group (nafamostat mesilate as anticoagulant, n=12) and non-anticoagulant group (n=15). The incidence of adverse events and the service life of the filter were compared between the two groups, and the coagulation indexes of the anticoagulation group during the treatment were further analyzed.

    Results

    The life of cardiopulmonary bypass through the first cannula was significantly longer than that in the non-anticoagulation group [(31.82±10.84) h vs (21.64±12.26) h, P=0.033]. The average service life of the filter during CRRT were also significantly longer than those in the non-anticoagulation group (P<0.05), Also, the incidence of bleeding events in the anticoagulation group was no increase throughout the treatment period.

    Conclusion

    It is safe and effective to use nafamostat mesilate as an anticoagulant in patients with high bleed risk after cardiovascular surgery during CRRT, which can effectively prolong the use time of the filter and no increase in the incidence of hemorrhagic complications.

  • Yan ZHANG, Na YIN, Haoshu DING
    World Clinical Drug. 2022, 43(9): 1148-1153.
    Objective

    To evaluate the efficacy and safety of nafamostat mesilate anticoagulation in patients treated with continuous renal replacement therapy (CRRT) in surgery intensive care unit (SICU) by retrospective study.

    Methods

    From January 2021 to March 2022, patients who were admitted to the department of anesthesia and critical care medicine, Xinhua hospital affiliated to Shanghai Jiao Tong university and treated with CRRT, with nafamostat mesilate (anticoagulation group) and no heparin dialysis regimen (no heparin group) were enrolled. The filter life, filter replacement rate and the incidence of extracorporeal circuit thrombosis were analyzed. The disseminated intravascular coagulation (DIC) index, platelet count, hemoglobin level, electrolytes, the occurrence of gastrointestinal bleeding, hematuria, cerebral hemorrhage and other bleeding conditions before and after CRRT in the anticoagulation group was compared, and pay attention to the cost of hospitalization and other economic indicators.

    Results

    A total of 53 CRRT treatments were completed in 14 patients treated with nafamostat mesilate. A total of 67 CRRT treatments were completed in 19 patients with heparin-free anticoagulation regimen. The coagulation change rate of the filter and pipeline in the anticoagulation group was lower than that in the no heparin group (5.66% vs 17.91%, P<0.05), and the average use time of the filter was longer than that in the non-heparin group [(10.31±2.65) h vs (7.28±1.87) h, P<0.05]. The DIC index and platelet count before and after CRRT were not affected by nafamostat mesilate anticoagulation (P>0.05). In the anticoagulant group, hyperkalemia did not occur during CRRT, and the difference in serum potassium was statistically significant compared with that before treatment (P<0.05), while the difference in serum sodium and serum chloride was not statistically significant (P>0.05).

    Conclusion

    Nafamostat mesilate is a safe and effective anticoagulant for patients treated with CRRT in SICU.

  • Hongli SU, Lingxia LI, Yanbin BAI, Yanling LIU
    World Clinical Drug. 2022, 43(9): 1154-1159.
    Objective

    To investigate the effects of dexmedetomidine on hemodynamics, immune function and stress response in patients with rectal cancer during perioperative period.

    Methods

    A total of 128 patients with rectal cancer who underwent radical resection in our hospital from January 2016 to February 2019 were selected and divided into observation group (n=64) and control group (n=64). In the observation group, dexmedetomidine was pumped intravenously 30 minutes before anesthesia induction until the end of the operation. Patients in the control group were given the same amount of normal saline. Other anesthesia methods were the same as those in the observation group. Heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), T-lymphocyte subsets (CD3+, CD4+, CD8+ and CD4+/CD8+) and natural killer (NK) cells were recorded before anesthesia induction (T1), immediately after surgery (T2), 30 minutes after surgery (T3) and 24 hours after surgery (T4). The levels of cortisol (CO), plasma epinephrine and norepinephrine were measured by enzyme-linked immunosorbent assay.

    Results

    Compared with T1, HR at T2 and T3 in the observation group was significantly slowed down and MAP was significantly decreased. However, the HR at T2 and T3 in the control group was significantly accelerated, and the MAP was significantly increased, The levels of HR and MAP at T2 and T3 time points in the study group were lower than those in the control group, and the differences between the two groups were statistically significant (P<0.013). The change of HR at T1 to T4 in the observation group was lower than those in the control group (P<0.05). Compared with T1 time point, the levels of CD3+, CD4+ and NK cells at T2, T3 and T4 time points in the two groups decreased (P<0.013); The levels of CD4+/CD8+ at T2, T3 and T4 time points in the control group decreased (P<0.013); CD4+/CD8+ in the observation group increased at T2 time point, while T3 and T4 time points decreased (P<0.013); The levels of CD3+, CD4+, CD8+, CD4+/CD8+ and NK cells in the observation group at T2 to T4 were higher than those in the control group (P<0.013). Compared with time point T1, the blood glucose, plasma adrenaline and noradrenaline levels at time points T2 to T4 in the control group increased (P<0.013). The levels of blood glucose, CO, plasma adrenaline and noradrenaline at T2 to T4 time points in the observation group were lower than those in the control group (P<0.013).

    Conclusion

    Dexmedetomidine can effectively maintain the stability of perioperative hemodynamics in patients with rectal cancer, improve cellular immune function, significantly reduce perioperative stress response and promote postoperative recovery of patients.

  • Haitao LYU, Qian HE, Xiaomei WAN, Lixin SUN
    World Clinical Drug. 2022, 43(9): 1160-1164.
    Objective

    To investigate the anesthetic effects of dexmedetomidine assisted general anesthesia in radical gastrectomy for gastric cancer and its effect on phosphofructokinase (PFK) and aldose reductase (AR), glucose-6-phosphate dehydrogenase (G6PD) and hemodynamics.

    Methods

    A total of 101 patients who underwent radical gastrectomy in Qingdao municipal hospital from December 2018 to December 2020 were retrospectively analyzed. The patients were divided into observation group (51 cases) and control group (50 cases) according to the anesthesia method. The control group was given conventional general anesthesia, while the observation group was given dexmedetomidine before induction of anesthesia. The anesthetic effect, PFK, AR, G6PD, heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), ventilation time, feeding time, getting out of bed time, postoperative hospital stay and complications before and after operation were compared between the two groups.

    Results

    The total excellent and good rate of the observation group (96.08%) was higher than that of the control group (82.00%), and the difference was statistically significant (P<0.05). After operation, serum PFK in the two groups decreased with time, and the observation group was higher than that in the control group (P<0.05). The levels of AR and G6PD in the two groups increased with time, and the observation group were lower than those in the control group (P<0.05). HR, SBP and DBP of the two groups were decreased with time, and the observation group were higher than those of the control group (P<0.05). The ventilation time, fluid feeding time, getting out of bed time and postoperative hospital stay in the observation group were lower than those in the control group, and the differences were statistically significant (P<0.05). The total incidence of complications in the observation group and the control group were 1.96% and 16.00%, respectively, and the difference was statistically significant (P<0.05).

    Conclusions

    The application of dexmedetomidine in patients undergoing radical gastrectomy has a significant effect, which can improve PFK, AR, G6PD and hemodynamics, and is safe and effective.

  • Yi JIAN, Zhaojing ZONG, Jianyong ZHANG
    World Clinical Drug. 2022, 43(9): 1165-1170.
  • Hua HUANG, Ping LI, Lin GUO, Xuemei GUO, Chuhui XIONG, Ya GAO, Yumeng YE
    World Clinical Drug. 2022, 43(9): 1171-1180.
    Objective

    To systematically evaluate the effectiveness and safety of secukinumab in the treatment of psoriatic arthritis (PA).

    Methods

    Relevant literature on the treatment of PA with secukinumab were searched in English databases (PubMed, MEDLINE, Embase, Cochrance Library) and the Chinese databases (CNKI, VIP, Wanfang), from January 2000 to December 2020. After quality evaluation of the literatures that met the inclusion criteria, the meta analysis was conducted with Revman 5.4 software.

    Results

    A total of 5 randomized controlled studies involving 2 455 patients with PA were included for analysis. Meta analysis results showed that compared with the treatment of the placebo group, the treatment group with secukinumab significantly improved the patients' remission of American College of Rheumatology (ACR) by 20%[odds ratio (OR)=4.40, 95% confidence interval (CI)(3.79, 5.11), P<0.000 01], ACR50 [OR=5.84, 95%CI (4.82, 7.07), P<0.000 01], ACR70[OR=7.98, 95%CI (5.64, 11.27), P<0.000 01], psoriatic area and severity index (PASI) 75[OR=9.72, 95%CI (6.68, 14.14), P<0.000 01] and PASI90[OR=7.75, 95%CI (4.92, 12.22), P<0.000 01]. Compared with the 150 mg group, the ACR20 in 300 mg secukinumab group was significantly improved [OR=1.36, 95%CI (1.04, 1.76), P=0.02]. In terms of safety, there was no significant difference in the incidence of overall adverse events and serious adverse events between the secukinumab group and the placebo group (P>0.05). The incidence of candida infection and tumor in the secukinumab group was significantly higher than that in the placebo group [OR=2.29, 95%CI (1.18, 4.46), P=0.01, OR=3.38, 95%CI (1.20, 9.53), P=0.02].

    Conclusion

    The efficacy and safety of secukinumab in the treatment of PA skin lesions and joint lesions are reliable. However, since secukinumab has just been marketed in China, there is no long-term clinical research report, and a large number of clinical studies and further verification are needed in the future.

  • Yanan JIANG, Xingyun HOU, Jiaoyang ZHENG
    World Clinical Drug. 2022, 43(9): 1181-1187.
News